SCHEMBL1795613

SCHEMBL1795613

CC(=O)OC1CC(=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18300021 0.91 CHRM2 (0.39)
SCHEMBL18300022 0.91 CHRM2 (0.39)
SCHEMBL5985695 0.82 TDP1 (0.40)
SCHEMBL13774729 0.82 CHRM2 (0.41)
SCHEMBL4100876 0.82 CHRM2 (0.41)
SCHEMBL11547378 0.82 TDP1 (0.40)
SCHEMBL14127634 0.82 CHRM2 (0.41)
SCHEMBL20053336 0.80 CHRM2 (0.37)
SCHEMBL8625426 0.80 CHRM2 (0.41)
SCHEMBL630437 0.79 CRBN (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12502376-B2 Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-23 US disclosed
US-12281102-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-22 US disclosed
WO-2024231436-A1 HYDROGENATION OF CYCLIC KETONES ARXADA AG (CH) 2024-11-14 WO disclosed
US-12116343-B2 Inhibitors of APOL1 and methods of using same VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-10-15 US disclosed
WO-2024139171-A1 IL-17A MODULATORS USYNOVA PHARMACEUTICALS, LTD. (CN) 2024-07-04 WO disclosed
WO-2024138286-A1 IL-17A MODULATORS USYNOVA PHARMACEUTICALS, LTD. (CN) 2024-07-04 WO disclosed
WO-2024027706-A1 BCL-XL DEGRADING COMPOUNDS BEIJING NEOX BIOTECH LIMITED (CN) 2024-02-08 WO disclosed
CN-117042769-A Substituted pyrrolopyrimidines and pyrazolopyrimidines as Bruton's Tyrosine Kinase (BTK) degrading agents 冰洲石生物科技公司 2023-11-10 CN disclosed
CN-116348447-A Inhibitors of APOL1 and methods of using the same 弗特克斯药品有限公司 2023-06-27 CN disclosed
WO-2023091726-A1 INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) SYROS PHARMACEUTICALS, INC. (US) 2023-05-25 WO disclosed
EP-1730119-A1 IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Incorporated (US) 2006-12-13 EP disclosed
US-7078529-B2 N-[1-(bi)cycloaliphatic-1H-imidazol-4-yl]-(bi)cycloaliphatic acetamides; central nervous system disorders; enzyme inhibitors of cyclin-dependent kinase-2 and -5, and glycogen synthase kinase-3 PFIZER INC. (US) 2006-07-18 US disclosed
US-20060149066-A1 Imidazole derivatives PFIZER INC 2006-07-06 US disclosed
WO-2005092864-A1 IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2005-10-06 WO disclosed
US-20040192750-A1 Antiproliferative agents; anticancer agents; neurodegenerative agents sexual disorders; antidiabetic agents; urogenital disorders; antidiabetic agents; obesity; muscular disorders; aftertreatment surgery; autoimmune disease PFIZER INC 2004-09-30 US disclosed
US-6756385-B2 FERTILITY; ANTIDIABETIC AGENTS PFIZER INC. 2004-06-29 US disclosed
EP-1305295-A1 IMIDAZOLE DERIVATIVES Pfizer Products Inc. (US) 2003-05-02 EP disclosed
US-20030083352-A1 Synthesis of imidazole intermediates PFIZER INC. 2003-05-01 US disclosed
US-20020119963-A1 Imidazole derivatives PFIZER PRODUCTS INC. 2002-08-29 US disclosed
WO-2002010141-A1 IMIDAZOLE DERIVATIVES PFIZER PRODUCTS INC. (US) 2002-02-07 WO disclosed